← Back to Home

U.S. Treasury Proposes Adding Biotechnology to Outbound Investment Controls, Creating New Hurdles for Cross-Border Fundraising

From biomanufacturing to automated laboratory tools, the U.S. is proposing broader national security restrictions on investment. Industry concerns center on overly broad rules affecting funding for innovation, but the proposal is not yet final, and the boundaries defining covered technologies and transactions will be key.

By SURL BioNews

Biotechnology companies’ cross-border fundraising and joint venture plans could face an additional national security hurdle. On October 22, the U.S. Department of the Treasury proposed draft rules to expand the Outbound Investment Security Program under the Comprehensive Outbound Investment National Security Act (COINS Act), bringing biotechnology within its scope. For companies seeking U.S. funding, whether future transactions can proceed will depend more heavily on the technologies involved, investment structures, and corporate control relationships.

The Treasury said the framework aims to prevent U.S. investment from helping countries of concern develop capabilities that threaten U.S. national security. The draft’s overall framework divides transactions into two categories: prohibited investments and those requiring notification. It applies to transactions involving certain covered foreign persons. For biotechnology, the official explanation lists proposed new investment prohibitions covering certain biologically derived compounds or materials, brain-computer interfaces, biomanufacturing equipment and facilities, and tools for biological design, sequencing, bioinformatics, and automated scientific discovery or experimentation.

These terms cover a broad range of activities, but they do not directly imply that all related research or companies will face restrictions. Whether an activity falls within the controls must still be assessed against the technical definitions and transaction conditions in the full rules. Official documents also designate China, including Hong Kong and Macau, as a country of concern and cover several other countries. Determining a company’s status involves ownership and control relationships as well as its location.

The funding channels subject to the rules extend beyond direct equity purchases. According to the Treasury’s FAQs, certain convertible debt, joint ventures, greenfield investments, and certain limited partnership investments in non-U.S. funds could also be covered. Based on the draft’s structure, companies and investors evaluating partnerships may therefore need to examine how funding enters a business, what rights it confers, and the technological activities of their prospective partners at the same time.

The draft also provides exceptions, including qualifying publicly traded securities and investment company securities. Another provision that can easily cause confusion is the exception for de minimis transactions totaling no more than $50,000 over the preceding 12 months: it applies only to notification obligations and does not mean that small investments can avoid the prohibitions. Whether a particular transaction qualifies for an exception remains subject to the relevant conditions.

Responding the same day, John F. Crowley, president and CEO of the U.S. Biotechnology Innovation Organization (BIO), acknowledged biotechnology’s strategic importance but warned that overly broad restrictions could increase uncertainty for innovators and investors and inadvertently weaken U.S. biotechnology competitiveness. This is the industry organization’s assessment of policy risks; the information currently available does not quantify any potential loss of funding or research and development resulting from the proposal.

The clearest upcoming deadline is December 7, 2026, when the public comment period closes. The draft itself has not brought the additional rules into effect. The Treasury will consider comments before issuing final rules and setting a separate effective date. For cross-border biotechnology partnerships, the next points to watch are how the final technological boundaries are drawn and whether the exceptions allow investors to clearly assess transaction risks.

References

  1. U.S. Department of the Treasury
  2. U.S. Department of the Treasury
  3. Biotechnology Innovation Organization